- Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
-
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.
- Bagnolini, Greta,Milano, Domenico,Manerba, Marcella,Schipani, Fabrizio,Ortega, Jose Antonio,Gioia, Dario,Falchi, Federico,Balboni, Andrea,Farabegoli, Fulvia,De Franco, Francesca,Robertson, Janet,Pellicciari, Roberto,Pallavicini, Isabella,Peri, Sebastiano,Minucci, Saverio,Girotto, Stefania,Di Stefano, Giuseppina,Roberti, Marinella,Cavalli, Andrea
-
p. 2588 - 2619
(2020/03/05)
-
- Novel peptides which are active on the central nervous system and have an action on the cholinergic system
-
The invention relates to peptides of the formula I in which R4 denotes an acyl group, R5 denotes D-Lys or Lys, A6 denotes the radical of phenylalanine, N-methylphenylalanine, 4- alkoxyphenylalanine or 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and R7 denotes a basic radical, processes for their preparation and their use.
- -
-
-
